Výsledky vyhledávání

Akademický článek

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.

Autor: Catlett IM; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA., Gao L; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA. Lu.Gao@bms.com., Hu Y; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA., Banerjee S; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA., Krueger JG; The Rockefeller University, New York, NY, USA.

Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2024 Oct; Vol. 14 (10), pp. 2827-2839. Date of Electronic Publication: 2024 Sep 16.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.

Autor: Johnson B; Translational Medicine, Immunology, Cardiovascular & Neuroscience Disease Team, Bristol Myers Squibb, Princeton, NJ, United States., Cheng L; Immunology Thematic Research Centers (TRC), Bristol Myers Squibb, Princeton, NJ, United States., Koenitzer J; Translational Medicine, Immunology, Cardiovascular & Neuroscience Disease Team, Bristol Myers Squibb, Princeton, NJ, United States., Catlett IM; Translational Medicine, Immunology, Cardiovascular & Neuroscience Disease Team, Bristol Myers Squibb, Princeton, NJ, United States., Schafer P; Translational Medicine, Immunology, Cardiovascular & Neuroscience Disease Team, Bristol Myers Squibb, Princeton, NJ, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Sep 30; Vol. 15, pp. 1437512. Date of Electronic Publication: 2024 Sep 30 (Print Publication: 2024).

Zobrazit plný text záznamu

Akademický článek

Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.

Autor: Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: p.conaghan@leeds.ac.uk., Nowak M; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Du S; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Luo Y; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Landis J; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Pachai C; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Fura A; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Catlett IM; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Grasela DM; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Østergaard M; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2023 May; Vol. 5 (5), pp. e263-e273.

Zobrazit plný text záznamu

Akademický článek

First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.

Autor: Catlett IM; Bristol Myers Squibb, Princeton, New Jersey, USA., Aras U; Bristol Myers Squibb, Princeton, New Jersey, USA., Hansen L; Bristol Myers Squibb, Princeton, New Jersey, USA., Liu Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Bei D; Bristol Myers Squibb, Princeton, New Jersey, USA., Girgis IG; Bristol Myers Squibb, Princeton, New Jersey, USA., Murthy B; Bristol Myers Squibb, Princeton, New Jersey, USA.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2023 Jan; Vol. 16 (1), pp. 151-164. Date of Electronic Publication: 2022 Nov 22.

Zobrazit plný text záznamu

Akademický článek

Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.

Autor: Catlett IM; Bristol Myers Squibb, Princeton, NJ. Electronic address: Ian.Catlett@bms.com., Hu Y; Bristol Myers Squibb, Princeton, NJ., Gao L; Bristol Myers Squibb, Princeton, NJ., Banerjee S; Bristol Myers Squibb, Princeton, NJ., Gordon K; The Medical College of Wisconsin, Milwaukee, Wisc., Krueger JG; The Rockefeller University, New York, NY.

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2022 Jun; Vol. 149 (6), pp. 2010-2020.e8. Date of Electronic Publication: 2021 Nov 10.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání